临床肺科杂志
臨床肺科雜誌
림상폐과잡지
JOUNAL OF CLINICAL PULMONARY MEDICINE
2014年
8期
1383-1385
,共3页
慢性肺源性心脏病%肺动脉高压%前列地尔%疗效
慢性肺源性心髒病%肺動脈高壓%前列地爾%療效
만성폐원성심장병%폐동맥고압%전렬지이%료효
chronic pulmonary heart disease%pulmonary hypertension%alprostadil%curative effect
目的：探讨前列地尔对慢性肺源性心脏病肺动脉高压的治疗效果,为临床提供参考。方法选择慢性肺源性心脏病伴肺动脉高压患者130例,随机分为两组,每组65例,对照组进行常规治疗,治疗组在对照组治疗基础上给予前列地尔治疗,比较两组疗效。结果治疗组患者治疗后,其DPAP、SPAP和MPAP的值分别为(11．9±2．5) mmHg、(28．6±3．8) mmHg、(16．3±2．5) mmHg,均较治疗前显著降低；对照组患者治疗后,其DPAP、SPAP和MPAP的值分别为(17．2±3．1) mmHg、(35．9±7．2) mmHg、(31．9±6．1) mmHg,均较治疗前显著降低；治疗组治疗后,DPAP与SPAP显著低于对照组；治疗组治疗后,PaO2、FEV1、FEV1/FVC的值分别为(66．84±8．03) mmHg、(81．41±11．13)%、(90．52±13．51)%,较治疗前显著升高,PaCO2值为(52．50±7．11) mmHg,较治疗前显著降低；对照组治疗后,PaO2、FEV1、FEV1/FVC的值分别为(55．88±7．72) mmHg、(77．39±12．11)%、(79．25±11．01)%,较治疗前显著升高,PaCO2值为(56．6±0．42) mmHg,较治疗前显著降低；治疗组患者治疗后的PaO2值显著高于对照组,差异均有统计学意义( P<0．05)。结论前列地尔治疗慢性肺源性心脏病肺动脉高压疗效显著,患者不良反应少,其临床效果优于常规治疗,用药后患者肺动脉压明显降低,症状得到明显缓解,说明前列地尔注射液在治疗慢性肺源性心脏病肺动脉高压方面具有较高的临床应用价值。
目的：探討前列地爾對慢性肺源性心髒病肺動脈高壓的治療效果,為臨床提供參攷。方法選擇慢性肺源性心髒病伴肺動脈高壓患者130例,隨機分為兩組,每組65例,對照組進行常規治療,治療組在對照組治療基礎上給予前列地爾治療,比較兩組療效。結果治療組患者治療後,其DPAP、SPAP和MPAP的值分彆為(11．9±2．5) mmHg、(28．6±3．8) mmHg、(16．3±2．5) mmHg,均較治療前顯著降低；對照組患者治療後,其DPAP、SPAP和MPAP的值分彆為(17．2±3．1) mmHg、(35．9±7．2) mmHg、(31．9±6．1) mmHg,均較治療前顯著降低；治療組治療後,DPAP與SPAP顯著低于對照組；治療組治療後,PaO2、FEV1、FEV1/FVC的值分彆為(66．84±8．03) mmHg、(81．41±11．13)%、(90．52±13．51)%,較治療前顯著升高,PaCO2值為(52．50±7．11) mmHg,較治療前顯著降低；對照組治療後,PaO2、FEV1、FEV1/FVC的值分彆為(55．88±7．72) mmHg、(77．39±12．11)%、(79．25±11．01)%,較治療前顯著升高,PaCO2值為(56．6±0．42) mmHg,較治療前顯著降低；治療組患者治療後的PaO2值顯著高于對照組,差異均有統計學意義( P<0．05)。結論前列地爾治療慢性肺源性心髒病肺動脈高壓療效顯著,患者不良反應少,其臨床效果優于常規治療,用藥後患者肺動脈壓明顯降低,癥狀得到明顯緩解,說明前列地爾註射液在治療慢性肺源性心髒病肺動脈高壓方麵具有較高的臨床應用價值。
목적：탐토전렬지이대만성폐원성심장병폐동맥고압적치료효과,위림상제공삼고。방법선택만성폐원성심장병반폐동맥고압환자130례,수궤분위량조,매조65례,대조조진행상규치료,치료조재대조조치료기출상급여전렬지이치료,비교량조료효。결과치료조환자치료후,기DPAP、SPAP화MPAP적치분별위(11．9±2．5) mmHg、(28．6±3．8) mmHg、(16．3±2．5) mmHg,균교치료전현저강저；대조조환자치료후,기DPAP、SPAP화MPAP적치분별위(17．2±3．1) mmHg、(35．9±7．2) mmHg、(31．9±6．1) mmHg,균교치료전현저강저；치료조치료후,DPAP여SPAP현저저우대조조；치료조치료후,PaO2、FEV1、FEV1/FVC적치분별위(66．84±8．03) mmHg、(81．41±11．13)%、(90．52±13．51)%,교치료전현저승고,PaCO2치위(52．50±7．11) mmHg,교치료전현저강저；대조조치료후,PaO2、FEV1、FEV1/FVC적치분별위(55．88±7．72) mmHg、(77．39±12．11)%、(79．25±11．01)%,교치료전현저승고,PaCO2치위(56．6±0．42) mmHg,교치료전현저강저；치료조환자치료후적PaO2치현저고우대조조,차이균유통계학의의( P<0．05)。결론전렬지이치료만성폐원성심장병폐동맥고압료효현저,환자불량반응소,기림상효과우우상규치료,용약후환자폐동맥압명현강저,증상득도명현완해,설명전렬지이주사액재치료만성폐원성심장병폐동맥고압방면구유교고적림상응용개치。
Objective To investigate the therapeutic effect of alprostadil on pulmonary hypertension of chronic pulmonary heart disease. Methods 130 patients with pulmonary hypertension of chronic pulmonary heart disease were randomly divided into two groups, 65 cases in each group. The control group was given conventional treatment, while the treatment group was additionally treated with alprostadil. The efficacy of the two groups was com-pared. Results After the treatment, the values of DPAP, SPAP and MPAP of the treatment group were ( 11. 9 ± 2. 5) mmHg, (28. 6 ± 3. 8) mmHg, and (16. 3 ± 2. 5) mmHg, which were significantly lower than those before treatment. The values of DPAP, SPAP and MPAP of the control group were ( 17. 2 ± 3. 1 ) mmHg, ( 35. 9 ± 7. 2 ) mmHg and (31. 9 ± 6. 1) mmHg, significantly lower than those before the treatment as well. The values of DPAP and SPAP were significantly lower in the treatment group than in the control group. The values of PaO2 , FEV1 and FEV1/FVC in the treatment group increased to 66. 84 ± 8. 03 mmHg, 81. 41% ± 11. 13% and 90. 52% ± 13. 51%, and the value of PaCO2 decreased to 52. 50 ± 7. 11 mmHg after the treatment. The values of PaO2 , FEV1 and FEV1/FVC in-creased to 55. 88 ± 7. 72 mmHg, 77. 39 ± 12. 11% and 79. 25 ± 11. 01%, and the value of PaCO2 decreased to 56. 6 ± 0. 42 mmHg respectively in the control group. The value of PaO2 was significantly higher in the treatment group than in the control group (P<0. 05). Conclusion Alprostadil injection shows good curative effect in the treatment of patients with pulmonary hypertension of chronic pulmonary heart disease, with less adverse reactions.
